JP2020517719A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517719A5 JP2020517719A5 JP2019558554A JP2019558554A JP2020517719A5 JP 2020517719 A5 JP2020517719 A5 JP 2020517719A5 JP 2019558554 A JP2019558554 A JP 2019558554A JP 2019558554 A JP2019558554 A JP 2019558554A JP 2020517719 A5 JP2020517719 A5 JP 2020517719A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- muscarinic receptor
- receptor antagonist
- nri
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 26
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 13
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 13
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 10
- -1 ediboxetine Chemical compound 0.000 claims 9
- 239000003149 muscarinic antagonist Substances 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 claims 7
- 229960002430 atomoxetine Drugs 0.000 claims 7
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 claims 7
- 229960005434 oxybutynin Drugs 0.000 claims 7
- 208000024891 symptom Diseases 0.000 claims 5
- 206010041235 Snoring Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 201000002859 sleep apnea Diseases 0.000 claims 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims 2
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229960001344 methylphenidate Drugs 0.000 claims 2
- 229960002748 norepinephrine Drugs 0.000 claims 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 2
- 229960003770 reboxetine Drugs 0.000 claims 2
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 claims 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims 2
- 229960002646 scopolamine Drugs 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- WYDUSKDSKCASEF-LJQANCHMSA-N (1s)-1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol Chemical compound C([C@](O)(C1CCCCC1)C=1C=CC=CC=1)CN1CCCC1 WYDUSKDSKCASEF-LJQANCHMSA-N 0.000 claims 1
- CBQGYUDMJHNJBX-OALUTQOASA-N (2S)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine Chemical compound CCOC1=CC=CC=C1O[C@@H](C=1C=CC=CC=1)[C@H]1OCCNC1 CBQGYUDMJHNJBX-OALUTQOASA-N 0.000 claims 1
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 claims 1
- GFRUPHOKLBPHTQ-UHFFFAOYSA-N 2-(2-cyclohexyl-2-hydroxy-1-oxo-2-phenylethoxy)ethyl-diethyl-methylammonium Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC[N+](C)(CC)CC)C1CCCCC1 GFRUPHOKLBPHTQ-UHFFFAOYSA-N 0.000 claims 1
- GKNPSSNBBWDAGH-UHFFFAOYSA-N 2-hydroxy-2,2-diphenylacetic acid (1,1-dimethyl-3-piperidin-1-iumyl) ester Chemical compound C1[N+](C)(C)CCCC1OC(=O)C(O)(C=1C=CC=CC=1)C1=CC=CC=C1 GKNPSSNBBWDAGH-UHFFFAOYSA-N 0.000 claims 1
- ZELFLGGRLLOERW-YECZQDJWSA-N 3-[(2r,3r)-1-(dimethylamino)-2-methylpentan-3-yl]phenol;hydrochloride Chemical compound Cl.CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 ZELFLGGRLLOERW-YECZQDJWSA-N 0.000 claims 1
- 229930003347 Atropine Natural products 0.000 claims 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims 1
- ZRYHPQCHHOKSMD-UHFFFAOYSA-N Hexocyclium Chemical compound C1C[N+](C)(C)CCN1CC(O)(C=1C=CC=CC=1)C1CCCCC1 ZRYHPQCHHOKSMD-UHFFFAOYSA-N 0.000 claims 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims 1
- JTPUMZTWMWIVPA-UHFFFAOYSA-O Isopropamide Chemical compound C=1C=CC=CC=1C(C(N)=O)(CC[N+](C)(C(C)C)C(C)C)C1=CC=CC=C1 JTPUMZTWMWIVPA-UHFFFAOYSA-O 0.000 claims 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 claims 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 claims 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims 1
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 claims 1
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 claims 1
- HBGWAZBZXJBYQD-UHFFFAOYSA-N amedalin Chemical compound C12=CC=CC=C2C(CCCNC)(C)C(=O)N1C1=CC=CC=C1 HBGWAZBZXJBYQD-UHFFFAOYSA-N 0.000 claims 1
- 229950000203 amedalin Drugs 0.000 claims 1
- 229960000836 amitriptyline Drugs 0.000 claims 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims 1
- 229960002519 amoxapine Drugs 0.000 claims 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 claims 1
- 229940118324 anisotropine Drugs 0.000 claims 1
- 229960000396 atropine Drugs 0.000 claims 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims 1
- 229960001081 benzatropine Drugs 0.000 claims 1
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 claims 1
- 229960000910 bethanechol Drugs 0.000 claims 1
- NZUPCNDJBJXXRF-UHFFFAOYSA-O bethanechol Chemical compound C[N+](C)(C)CC(C)OC(N)=O NZUPCNDJBJXXRF-UHFFFAOYSA-O 0.000 claims 1
- 229960003003 biperiden Drugs 0.000 claims 1
- YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical compound C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 claims 1
- 229960001058 bupropion Drugs 0.000 claims 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 1
- RICLFGYGYQXUFH-UHFFFAOYSA-N buspirone hydrochloride Chemical compound [H+].[Cl-].C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 RICLFGYGYQXUFH-UHFFFAOYSA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- XGGHHHBGPSNXFE-ZSHCYNCHSA-N chembl1186610 Chemical compound C1[C@H](OC(=O)C(CCC)CCC)C[C@@H]2CC[C@H]1[N+]2(C)C XGGHHHBGPSNXFE-ZSHCYNCHSA-N 0.000 claims 1
- 229960003154 clidinium Drugs 0.000 claims 1
- HOOSGZJRQIVJSZ-NNBUQUNQSA-N clidinium Chemical compound C1([C@H]2CC[N@+](CC2)(C1)C)OC(=O)C(O)(C=1C=CC=CC=1)C1=CC=CC=C1 HOOSGZJRQIVJSZ-NNBUQUNQSA-N 0.000 claims 1
- HLOCJJORRHQDKS-UHFFFAOYSA-N cp-39,332 Chemical compound C12=CC=CC=C2CC(NC)CC1C1=CC=CC=C1 HLOCJJORRHQDKS-UHFFFAOYSA-N 0.000 claims 1
- YFAIJBZEDDOCAN-UHFFFAOYSA-N daledalin Chemical compound C12=CC=CC=C2C(CCCNC)(C)CN1C1=CC=CC=C1 YFAIJBZEDDOCAN-UHFFFAOYSA-N 0.000 claims 1
- 229950009245 daledalin Drugs 0.000 claims 1
- 229960002677 darifenacin Drugs 0.000 claims 1
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 claims 1
- 229960001623 desvenlafaxine Drugs 0.000 claims 1
- CURUTKGFNZGFSE-UHFFFAOYSA-N dicyclomine Chemical compound C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 claims 1
- 229960002777 dicycloverine Drugs 0.000 claims 1
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 claims 1
- 229960004890 diethylpropion Drugs 0.000 claims 1
- OGAKLTJNUQRZJU-UHFFFAOYSA-N diphenidol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)CCCN1CCCCC1 OGAKLTJNUQRZJU-UHFFFAOYSA-N 0.000 claims 1
- 229960003520 diphenidol Drugs 0.000 claims 1
- 229960005426 doxepin Drugs 0.000 claims 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims 1
- 229950008247 esreboxetine Drugs 0.000 claims 1
- 229960002978 fesoterodine Drugs 0.000 claims 1
- DCCSDBARQIPTGU-HSZRJFAPSA-N fesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)OC(=O)C(C)C)=CC=CC=C1 DCCSDBARQIPTGU-HSZRJFAPSA-N 0.000 claims 1
- 229940015042 glycopyrrolate Drugs 0.000 claims 1
- 229960001666 hexocyclium Drugs 0.000 claims 1
- 229960004801 imipramine Drugs 0.000 claims 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims 1
- 229960001737 isopropamide Drugs 0.000 claims 1
- 229950004863 lortalamine Drugs 0.000 claims 1
- MJRPHRMGEKCADU-JVLSTEMRSA-N lortalamine Chemical compound C12=CC(Cl)=CC=C2O[C@]23CCN(C)C[C@@H]2[C@H]1CC(=O)N3 MJRPHRMGEKCADU-JVLSTEMRSA-N 0.000 claims 1
- OZGPVYJHWWPEFT-RGNHYFCHSA-N manifaxine Chemical compound C[C@@H]1N[C@H](C)CO[C@@]1(O)C1=CC(F)=CC(F)=C1 OZGPVYJHWWPEFT-RGNHYFCHSA-N 0.000 claims 1
- 229950006048 manifaxine Drugs 0.000 claims 1
- 229960003092 mepenzolate Drugs 0.000 claims 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims 1
- 229960005103 metixene Drugs 0.000 claims 1
- MJFJKKXQDNNUJF-UHFFFAOYSA-N metixene Chemical compound C1N(C)CCCC1CC1C2=CC=CC=C2SC2=CC=CC=C21 MJFJKKXQDNNUJF-UHFFFAOYSA-N 0.000 claims 1
- ITJNARMNRKSWTA-UHFFFAOYSA-N nisoxetine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=CC=C1OC ITJNARMNRKSWTA-UHFFFAOYSA-N 0.000 claims 1
- 229950004211 nisoxetine Drugs 0.000 claims 1
- 229960001158 nortriptyline Drugs 0.000 claims 1
- 229940083311 nucynta Drugs 0.000 claims 1
- 208000001797 obstructive sleep apnea Diseases 0.000 claims 1
- 229960002740 oxyphenonium Drugs 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 229960005253 procyclidine Drugs 0.000 claims 1
- 229960002601 protriptyline Drugs 0.000 claims 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 claims 1
- 229950010561 radafaxine Drugs 0.000 claims 1
- RCOBKSKAZMVBHT-TVQRCGJNSA-N radafaxine Chemical compound C[C@@H]1NC(C)(C)CO[C@@]1(O)C1=CC=CC(Cl)=C1 RCOBKSKAZMVBHT-TVQRCGJNSA-N 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 229960003855 solifenacin Drugs 0.000 claims 1
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 claims 1
- BRPOADLGOFPKKJ-UHFFFAOYSA-N tandamine Chemical compound C12=CC=CC=C2N(CC)C2=C1CCSC2(C)CCN(C)C BRPOADLGOFPKKJ-UHFFFAOYSA-N 0.000 claims 1
- 229950006964 tandamine Drugs 0.000 claims 1
- 229960005126 tapentadol Drugs 0.000 claims 1
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 claims 1
- 229960004045 tolterodine Drugs 0.000 claims 1
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 claims 1
- 229960001032 trihexyphenidyl Drugs 0.000 claims 1
- 229960001491 trospium Drugs 0.000 claims 1
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 claims 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 claims 1
- 229960004688 venlafaxine Drugs 0.000 claims 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 1
- 229960001255 viloxazine Drugs 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023108387A JP2023139000A (ja) | 2017-04-28 | 2023-06-30 | 睡眠時無呼吸を治療する方法及び組成物 |
| JP2025128090A JP2025169279A (ja) | 2017-04-28 | 2025-07-31 | 睡眠時無呼吸を治療する方法及び組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762491504P | 2017-04-28 | 2017-04-28 | |
| US62/491,504 | 2017-04-28 | ||
| US201762558814P | 2017-09-14 | 2017-09-14 | |
| US62/558,814 | 2017-09-14 | ||
| PCT/US2018/029518 WO2018200775A1 (en) | 2017-04-28 | 2018-04-26 | Methods and compositions for treating sleep apnea |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023108387A Division JP2023139000A (ja) | 2017-04-28 | 2023-06-30 | 睡眠時無呼吸を治療する方法及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517719A JP2020517719A (ja) | 2020-06-18 |
| JP2020517719A5 true JP2020517719A5 (enExample) | 2021-06-10 |
| JP7373997B2 JP7373997B2 (ja) | 2023-11-06 |
Family
ID=63918622
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019558554A Active JP7373997B2 (ja) | 2017-04-28 | 2018-04-26 | 睡眠時無呼吸を治療する方法及び組成物 |
| JP2023108387A Pending JP2023139000A (ja) | 2017-04-28 | 2023-06-30 | 睡眠時無呼吸を治療する方法及び組成物 |
| JP2025128090A Pending JP2025169279A (ja) | 2017-04-28 | 2025-07-31 | 睡眠時無呼吸を治療する方法及び組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023108387A Pending JP2023139000A (ja) | 2017-04-28 | 2023-06-30 | 睡眠時無呼吸を治療する方法及び組成物 |
| JP2025128090A Pending JP2025169279A (ja) | 2017-04-28 | 2025-07-31 | 睡眠時無呼吸を治療する方法及び組成物 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US11123313B2 (enExample) |
| EP (1) | EP3615016A4 (enExample) |
| JP (3) | JP7373997B2 (enExample) |
| KR (3) | KR102682159B1 (enExample) |
| CN (2) | CN110799181A (enExample) |
| AU (3) | AU2018260666B2 (enExample) |
| BR (1) | BR112019022483A2 (enExample) |
| CA (1) | CA3061468A1 (enExample) |
| CO (1) | CO2019013180A2 (enExample) |
| CR (1) | CR20190546A (enExample) |
| DO (1) | DOP2019000274A (enExample) |
| EC (1) | ECSP19084058A (enExample) |
| GE (4) | GEAP202416602A (enExample) |
| MA (1) | MA49069A (enExample) |
| MX (2) | MX394941B (enExample) |
| MY (1) | MY200172A (enExample) |
| NI (1) | NI201900110A (enExample) |
| PH (1) | PH12019502427A1 (enExample) |
| SG (2) | SG10202111623TA (enExample) |
| UA (1) | UA127759C2 (enExample) |
| WO (1) | WO2018200775A1 (enExample) |
| ZA (1) | ZA201907158B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11123313B2 (en) * | 2017-04-28 | 2021-09-21 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treating sleep apnea |
| CA3089712A1 (en) * | 2018-01-30 | 2019-08-08 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
| CN108309261B (zh) * | 2018-02-11 | 2020-05-22 | 西安交通大学 | 一种猝死预警方法及装置和系统 |
| US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
| US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| MX2021004883A (es) * | 2018-10-31 | 2021-08-05 | Apnimed Inc Delaware | Metodos y composiciones para tratar apnea del sue?o. |
| CA3129270A1 (en) | 2019-02-08 | 2020-08-13 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treating sleep apnea |
| US20220362221A1 (en) * | 2019-11-04 | 2022-11-17 | Apnimed, Inc. (Delaware) | Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea |
| CA3177654A1 (en) | 2020-05-05 | 2021-11-11 | Dennis MOLNAR | Polymorphic forms of (r)-oxybutynin hydrochloride |
| CN114159568B (zh) * | 2020-09-11 | 2025-08-01 | 北京原基华毅生物科技有限公司 | Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用 |
| RU2757470C1 (ru) * | 2020-11-19 | 2021-10-18 | Ренат Рашитович Ахмеров | Способ лечения храпа с помощью введения тромбоцитарной аутологичной плазмы |
| US20240075035A1 (en) * | 2021-01-14 | 2024-03-07 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
| AU2022231133A1 (en) * | 2021-03-04 | 2023-09-21 | Apnimed, Inc. (Delaware) | Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea |
| US20240189328A1 (en) * | 2021-04-16 | 2024-06-13 | Apnimed, Inc. (Delaware) | Combination of norepinephrine reuptake inhibitor and a cannabinoid for use in treating sleep apnea |
| BR112023026158A2 (pt) * | 2021-06-17 | 2024-03-05 | Apnimed Inc Delaware | Inibidores da recaptação de norepinefrina para tratamento da apneia do sono |
| CN117956959A (zh) * | 2021-08-31 | 2024-04-30 | 爱普宁公司(特拉华) | 用于治疗睡眠呼吸暂停的方法和组合物 |
| CA3259605A1 (en) * | 2021-12-22 | 2023-06-29 | Bayer Aktiengesellschaft | Combination of a task1/3 channel blocker with a norepinephrine reuptake inhibitor for the treatment of sleep apnea |
| CA3259602A1 (en) | 2021-12-22 | 2023-06-29 | Bayer Aktiengesellschaft | Combination of an .alpha.2-adrenoceptor subtype c (alpha-2c) antagonists with a muscarinic receptor antagonist for the treatment of sleep apnea |
| CN118475347A (zh) | 2021-12-22 | 2024-08-09 | 拜耳公司 | 用于治疗睡眠呼吸暂停的α2-肾上腺素受体亚型C（α-2C）拮抗剂与降肾上腺素重摄取抑制剂的结合物 |
| EP4522149A1 (en) * | 2022-05-13 | 2025-03-19 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000071108A2 (en) | 1999-05-20 | 2000-11-30 | Sepracor Inc. | Methods for treatment of asthma using s-oxybutynin |
| NZ520975A (en) * | 2000-02-24 | 2004-03-26 | Upjohn Co | New drug combinations containing a norepinephrine reuptake inhibitor and an antimuscarinic agent for treating nervous system disorders |
| WO2006023703A2 (en) * | 2004-08-20 | 2006-03-02 | Cypress Bioscience, Inc. | Method for treating sleep related breathing disorders |
| CN101132777A (zh) * | 2004-12-20 | 2008-02-27 | 科利吉姆制药公司 | 用于睡眠障碍的药物组合物 |
| CN107007602A (zh) * | 2011-01-28 | 2017-08-04 | 辉达斯医学研究所 | 治疗阻塞性睡眠呼吸暂停的方法 |
| US11123313B2 (en) * | 2017-04-28 | 2021-09-21 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treating sleep apnea |
| CA3089712A1 (en) * | 2018-01-30 | 2019-08-08 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
-
2018
- 2018-04-26 US US16/609,048 patent/US11123313B2/en active Active
- 2018-04-26 CN CN201880042623.1A patent/CN110799181A/zh active Pending
- 2018-04-26 CR CR20190546A patent/CR20190546A/es unknown
- 2018-04-26 KR KR1020197034523A patent/KR102682159B1/ko active Active
- 2018-04-26 MX MX2019012729A patent/MX394941B/es unknown
- 2018-04-26 WO PCT/US2018/029518 patent/WO2018200775A1/en not_active Ceased
- 2018-04-26 CN CN202411366994.9A patent/CN119185558A/zh active Pending
- 2018-04-26 MA MA049069A patent/MA49069A/fr unknown
- 2018-04-26 CA CA3061468A patent/CA3061468A1/en active Pending
- 2018-04-26 GE GEAP202416602A patent/GEAP202416602A/en unknown
- 2018-04-26 BR BR112019022483-1A patent/BR112019022483A2/pt unknown
- 2018-04-26 UA UAA201910615A patent/UA127759C2/uk unknown
- 2018-04-26 EP EP18791670.5A patent/EP3615016A4/en active Pending
- 2018-04-26 SG SG10202111623TA patent/SG10202111623TA/en unknown
- 2018-04-26 MY MYPI2019006319A patent/MY200172A/en unknown
- 2018-04-26 JP JP2019558554A patent/JP7373997B2/ja active Active
- 2018-04-26 AU AU2018260666A patent/AU2018260666B2/en active Active
- 2018-04-26 KR KR1020257032249A patent/KR20250145704A/ko active Pending
- 2018-04-26 SG SG11201909973U patent/SG11201909973UA/en unknown
- 2018-04-26 KR KR1020247009759A patent/KR20240042261A/ko not_active Ceased
- 2018-04-26 GE GEAP201815226A patent/GEP20227387B/en unknown
- 2018-04-26 GE GEAP201815757A patent/GEP20247617B/en unknown
- 2018-04-26 GE GEAP201816320A patent/GEP20257788B/en unknown
-
2019
- 2019-10-24 MX MX2022010349A patent/MX2022010349A/es unknown
- 2019-10-25 PH PH12019502427A patent/PH12019502427A1/en unknown
- 2019-10-25 NI NI201900110A patent/NI201900110A/es unknown
- 2019-10-25 DO DO2019000274A patent/DOP2019000274A/es unknown
- 2019-10-29 ZA ZA2019/07158A patent/ZA201907158B/en unknown
- 2019-11-25 EC ECSENADI201984058A patent/ECSP19084058A/es unknown
- 2019-11-26 CO CONC2019/0013180A patent/CO2019013180A2/es unknown
-
2021
- 2021-09-10 US US17/471,892 patent/US20210401777A1/en not_active Abandoned
-
2022
- 2022-09-27 AU AU2022241471A patent/AU2022241471A1/en not_active Abandoned
-
2023
- 2023-06-30 JP JP2023108387A patent/JP2023139000A/ja active Pending
- 2023-07-19 US US18/355,178 patent/US20240189261A1/en not_active Abandoned
-
2024
- 2024-03-04 US US18/594,885 patent/US20240261239A1/en not_active Abandoned
-
2025
- 2025-07-31 JP JP2025128090A patent/JP2025169279A/ja active Pending
- 2025-09-11 AU AU2025230729A patent/AU2025230729A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517719A5 (enExample) | ||
| JP2023139000A5 (enExample) | ||
| JP6824314B2 (ja) | アカンプロサート製剤、それを用いる方法、およびそれを含む合剤 | |
| TWI554271B (zh) | 用於治療巴金森氏症的類鴉片激動劑與類鴉片拮抗劑之組合 | |
| KR20250145704A (ko) | 수면 무호흡을 치료하기 위한 방법 및 조성물 | |
| JP2020079277A (ja) | ブプレノルフィンの乱用抵抗性粘膜付着性送達デバイス | |
| JP2009525343A5 (enExample) | ||
| JP2006506378A5 (enExample) | ||
| JP2021120379A5 (enExample) | ||
| JP2008535867A5 (enExample) | ||
| RU2007140348A (ru) | Способы и композиции для лечения заболеваний цнс | |
| SG189395A1 (en) | Antitussive compositions comprising memantine | |
| CN101730530A (zh) | 他喷他多的滴定 | |
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| JP2009536176A5 (enExample) | ||
| JP2011509295A5 (enExample) | ||
| Bied et al. | A critical appraisal of the selegiline transdermal system for major depressive disorder | |
| AU2017238051B2 (en) | Treatment of uremic pruritus | |
| US20180125840A1 (en) | Treatment of prurigo nodularis | |
| Verma et al. | Antihypertensive efficacy of carvedilol and amlodipine in patients of mild to moderate hypertension–a comparative study | |
| EP2830605B1 (en) | A combination medicament comprising phenylephrine and paracetamol | |
| US11207330B2 (en) | Mirtazapine for use in medication overuse headache based on tension-type headache | |
| CN106660936A (zh) | 用于治疗adhd的方法和达斯曲林(dasotraline)组合物 | |
| US20120190752A1 (en) | Exo-s-mecamylamine method, use, and compound for treatment | |
| AU2017202884B2 (en) | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |